IMMUNOLOGICAL INDICATORS OF TUBERCULOSIS INFECTION IN ADULTS AND THEIR ASSOCIATION WITH DISEASE SEVERITY
- Authors
-
-
Rozikhon Khakimova
Candidate of Medical Sciences Department of Phthisiology and Pulmonology Andijan State Medical Institute, Republic of Uzbekistan
Author
-
- Keywords:
- Tuberculosis, immunological indicators, cytokines, cellular immunity, disease severity, inflammation, adults, pulmonary tuberculosis.
- Abstract
-
Tuberculosis (TB) remains one of the leading infectious causes of morbidity and mortality worldwide. The clinical course and severity of tuberculosis infection in adults are determined not only by the virulence of Mycobacterium tuberculosis (Mtb) but also by the host immune response. The present study aims to analyze key immunological indicators in adults with pulmonary tuberculosis and to evaluate their association with disease severity. A comprehensive assessment of cellular and humoral immune parameters, cytokine profiles, and inflammatory biomarkers was performed in adult patients with varying degrees of disease severity. The findings demonstrate that severe forms of tuberculosis are characterized by pronounced alterations in T-lymphocyte subpopulations, increased pro-inflammatory cytokine levels (TNF-α, IL-6, IFN-γ), elevated acute-phase reactants, and evidence of immune dysregulation. The imbalance between protective cellular immunity and excessive inflammatory response appears to play a central role in disease progression. These results underline the importance of immunological monitoring in tuberculosis management and provide insights into prognostic markers and potential immunomodulatory therapeutic strategies.
- References
-
1.World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.
2.Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.
3.O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475–527.
4.Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. 2017;17(11):691–702.
5.Dorhoi A, Kaufmann SHE. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin Immunopathol. 2016;38(2):153–166.
6.Scriba TJ, Coussens AK, Fletcher HA. Human immunology of tuberculosis. Microbiol Spectr. 2017;5(1):TBTB2-0016-2016.
7.Mayer-Barber KD, Sher A. Cytokine and lipid mediator networks in tuberculosis. Immunol Rev. 2015;264(1):264–275.
8.Gideon HP, Flynn JL. Latent tuberculosis: what the host “sees”? Immunol Res. 2011;50(2-3):202–212.
9.Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466(7309):973–977.
10.DiNardo AR, Nishiguchi T, Grimm SL, Schlesinger LS. Tuberculosis immunology in 2020: state of the art and future directions. J Infect Dis. 2020;221(Suppl 3):S149–S157.
11.Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet. 2016;387(10024):1211–1226.
12.Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010;185(1):15–22.
13.Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387(10035):2312–2322.
14.Achkar JM, Chan J. Casadevall A. Role of antibodies in tuberculosis: emerging concepts and clinical implications. Front Immunol. 2015;6:138.
15.Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol. 2015;15(4):255–263.
- Downloads
- Published
- 2026-05-23
- Issue
- Vol. 2 No. 5 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
